A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

Conditions: Vitiligo Interventions: Drug: Ritlecitinib; Drug: Ritlecitinib 100 mg; Drug: Placebo Sponsors: Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials